TY - JOUR
T1 - T cell receptor peptide therapy for autoimmune disease
AU - Vandenbark, Arthur A.
AU - Chou, Yuan K.
AU - Bourdette, Dennis N.
AU - Whitham, Ruth
AU - Hashim, George A.
AU - Offner, Halina
N1 - Funding Information:
This work was supported by the Department of Veterans Affairs, grants NS23221, NS23444 and NS21466 from the Department of Health and Human Services, the Margaret T Biddle Foundation and by XOMA Corporation.
PY - 1992/4
Y1 - 1992/4
N2 - Synthetic peptides corresponding to germline T cell receptor (TCR) Vβ sequences shared by encephalitogenic T cells can prevent and treat experimental autoimmune encephalomyelitis in rats. The operative mechanism apparently involves boosting of anti-TCR immunity that develops during the course of experimental autoimmune encephalomyelitis (EAE), leading to the induction of autoregulatory T cells and antibodies. Striking parallels are present between patients with multiple sclerosis and animals with EAE in the T cell frequency and TCR V gene bias of BP reactive T cells, suggesting the involvement of an encephalitogenic process in multiple sclerosis. Preliminary trials with the appropriate human TCR peptides indicate that anti-TCR immunity can be boosted efficiently and safely, with concomitant loss of BP response, thus providing an effective strategy for selective regulation of autoimmunity in man.
AB - Synthetic peptides corresponding to germline T cell receptor (TCR) Vβ sequences shared by encephalitogenic T cells can prevent and treat experimental autoimmune encephalomyelitis in rats. The operative mechanism apparently involves boosting of anti-TCR immunity that develops during the course of experimental autoimmune encephalomyelitis (EAE), leading to the induction of autoregulatory T cells and antibodies. Striking parallels are present between patients with multiple sclerosis and animals with EAE in the T cell frequency and TCR V gene bias of BP reactive T cells, suggesting the involvement of an encephalitogenic process in multiple sclerosis. Preliminary trials with the appropriate human TCR peptides indicate that anti-TCR immunity can be boosted efficiently and safely, with concomitant loss of BP response, thus providing an effective strategy for selective regulation of autoimmunity in man.
UR - http://www.scopus.com/inward/record.url?scp=0026505191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026505191&partnerID=8YFLogxK
U2 - 10.1016/0896-8411(92)90023-J
DO - 10.1016/0896-8411(92)90023-J
M3 - Article
C2 - 1503638
AN - SCOPUS:0026505191
SN - 0896-8411
VL - 5
SP - 83
EP - 92
JO - Journal of Autoimmunity
JF - Journal of Autoimmunity
IS - SUPPL. A
ER -